Poop pills plus biologics: a new hope for ulcerative colitis?

NCT ID NCT05327790

Recruiting now Disease control Sponsor: University of Alberta Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether adding a freeze-dried fecal microbiota transplant (FMT) to standard biologic drugs (vedolizumab or ustekinumab) helps people with ulcerative colitis reach remission more safely and effectively. About 40 adults with active UC will receive either FMT or a placebo alongside their biologic. The study focuses on safety and remission rates over 24 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Fecal microbiota transplant (FMT) combined with vedolizumab or ustekinumab
What this could lead to: If it works, this could point toward a safer, more effective way to induce remission in ulcerative colitis by combining gut bacteria therapy with standard biologics.
What could go wrong: This is a small, early-phase pilot trial with only 40 participants. The added benefit of FMT over biologics alone is unproven, and there are risks of infection or worsening colitis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ULCERATIVE COLITIS

Contacts and locations

Locations

University of Alberta Hospital
RECRUITING

Edmonton, Alberta, T6G 2X8, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.